Aug 27 (Reuters) - Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck’s Zetia lowered cholesterol level by 35 percent in a late-stage study. The study evaluated the efficacy and safety of the bempedoic acid-ezetimibe combination pill compared with bempedoic acid, ezetimibe or placebo in 382 high-risk patients. The 12-week study showed a 35 percent reduction in low-density lipoprotein cholesterol (LDL-C) for the combination pill compared to a 3 percent for placebo, 24 percent for ezetimibe and 20 percent for bempedoic acid.
Shares of the company rose 2 percent to $50 in premarket trading. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)